Publications by authors named "Motohiro Tamiya"

Claim this Profile
C
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Takashi Kijima, Nobuyo Tamiya

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.
Nao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, Kiyohide Komuta, Akito Miyazaki, Motohiro Tamiya, Akihiro Tamiya

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).
Yoshihiko Sakata, Go Saito, Shinya Sakata, Teppei Yamaguchi, Motohiro Tamiya

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].
Akihiro Tsukaguchi, Kinnosuke Matsumoto, Akihiro Tamiya, Motohiro Tamiya, Masahide Mori

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC.
Kensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, Akihiro Tsukaguchi, Nao Shoshihara, Akihiro Tamiya, Motohiro Tamiya

JTO Clin Res Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment.
Yuki Iwahashi, Akihiro Tamiya, Tsunehiro Tanaka, Motohiro Tamiya, Akihiro Tsukaguchi

Anticancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Yusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Nobuyo Tamiya

Transl Lung Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.
Akihiro Tsukaguchi, Kinnosuke Matsumoto, Akihiro Tamiya, Motohiro Tamiya, Masahide Mori

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non-Small Cell Lung Cancer.
Tsunehiro Tanaka, Motohiro Tamiya, Akito Miyazaki, Kiyohide Komura, Shun Futamura

Thorac Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
Toshiya Fujisaki, Eisaku Miyauchi, Gen Kida, Yu Miura, Kana Watanabe, Motohiro Tamiya

Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.
Asuka Okada, Yoshihiko Sakata, Yuko Oya, Shinya Sakata, Teppei Yamaguchi, Motohiro Tamiya

Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study.
Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka, Katsunori Shinozaki

Cancer Res Commun· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation.
Koichi Ogawa, Hiroyasu Kaneda, Yasuhiro Koh, Yoshiya Matsumoto, Kenji Sawa, Motohiro Tamiya

Cancer Diagn Progn· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan.
Satoshi Miyamoto, Akihiro Tsukaguchi, Hanako Kuhara, Taiichiro Otsuki, Takayuki Shiroyama, Motohiro Tamiya, Akihiro Tamiya

Thorac Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report.
Kiyohide Komuta, Kei Kunimasa, Akito Miyazaki, Shun Futamura, Tsunehiro Tanaka, Motohiro Tamiya

Case Rep Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade.
Hitomi Nishinakamura, Sayoko Shinya, Takuma Irie, Shugo Sakihama, Takeo Naito, Motohiro Tamiya

Sci Transl Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).
Nobuyuki Katakami, Kazuma Nagata, Akiyoshi Nakakura, Tadashi Okamoto, Toshihiko Kaneda, Motohiro Tamiya

Jpn J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, Akito Hata, Hirotaka Matsumoto

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, Koji Haratani, Motohiro Tamiya

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report.
Kei Kunimasa, Akito Miyazaki, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura

Thorac Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Hayato Kawachi, Motohiro Tamiya, Yuko Oya, Go Saito, Yoshihiko Taniguchi

Clin Lung Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
Akito Hata, Nobuyuki Katakami, Naoto Takase, Kayoko Kibata, Yuta Yamanaka, Motohiro Tamiya

Lung Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).
Kageaki Watanabe, Keita Sasaki, Ryunosuke Machida, Junichi Shimizu, Yuki Yamane, Motohiro Tamiya

Jpn J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Yusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Nobuyo Tamiya

Invest New Drugs· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Ryota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, Yoko Tsukita, Ichiro Nakachi, Motohiro Tamiya

Lung Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis